ERBB2 and liver cancer: Lin Z et al[55] found that miR-372 can inhibit β-catenin degradation, promote β-catenin/TCF4 transcriptional activity, increase PKM2 expression, make PKM2 dimer translocation into the nucleus and acetylate histone H3 lysine at erbB-2 promoter region, thereby increasing erbB-2 expression and promoting liver cancer occurrence.